Nina Reschke

Title: Nina Reschke: Innovator in Multi-Specific T-Cell Engagers

Introduction

Nina Reschke is a prominent inventor based in Schlieren, Switzerland. She has made significant contributions to the field of biotechnology, particularly in the development of multi-specific proteins for therapeutic applications. Her work focuses on innovative solutions for treating diseases, including cancer.

Latest Patents

Nina Reschke holds a patent for her invention titled "DARPin based multi-specific T-cell engagers." This invention relates to recombinant multi-specific proteins that comprise binding agents with specificity for various targets, such as CD3, CD33, CD123, and CD70. The patent also covers nucleic acids encoding these multi-specific proteins, pharmaceutical compositions that include these proteins or nucleic acids, and their use in methods for treating or diagnosing diseases, particularly acute myeloid leukaemia (AML) in mammals, including humans.

Career Highlights

Nina Reschke is associated with Molecular Partners AG, a company known for its innovative approaches in the field of protein therapeutics. Her work has been instrumental in advancing the understanding and application of multi-specific proteins in medical treatments.

Collaborations

Nina collaborates with notable colleagues, including Sebastian Grimm and Christian Reichen. Their combined expertise contributes to the ongoing research and development efforts at Molecular Partners AG.

Conclusion

Nina Reschke's contributions to the field of biotechnology, particularly through her patent on multi-specific T-cell engagers, highlight her role as an innovator in medical science. Her work continues to pave the way for new therapeutic strategies in the fight against cancer.